Dabigatran: A cause of hematologic emergency

Yasir Lal, Joel Van Heukelom

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Dabigatran etexilate, a direct thrombin inhibitor, has become an alternative to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. There remains a concern about its overdose and life-threatening hemorrhage because of unavailability of appropriate coagulation tests to monitor and antidotes to reverse its effects. There are no clinical data about its safety in patients with fluctuating renal function. Multiple bleeding events reported with dabigatran have prompted the U.S. Food and Drug Administration to further investigate these reports. Four clinical cases with life-threatening bleeding, strategies that were used to achieve hemostasis and a brief literature review to demonstrate the hematologic emergency caused by dabigatran are presented in this study.

Original languageEnglish (US)
Pages (from-to)190-193
Number of pages4
JournalAmerican Journal of the Medical Sciences
Issue number3
StatePublished - 2013
Externally publishedYes


  • Anticoagulant.
  • Antidote
  • Dabigatran
  • Hemorrhage
  • Pradaxa

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Dabigatran: A cause of hematologic emergency'. Together they form a unique fingerprint.

Cite this